Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE‐MI): design and baseline characteristics

Patients surviving an acute myocardial infarction (AMI) are at risk of developing symptomatic heart failure (HF) or premature death. We hypothesized that sacubitril/valsartan, effective in the treatment of chronic HF, prevents development of HF and reduces cardiovascular death following high‐risk AMI compared to a proven angiotensin‐converting enzyme (ACE) inhibitor. This paper describes the study design and baseline characteristics of patients enrolled in the Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE‐MI) trial.

[1]  Deepak L. Bhatt,et al.  2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2020, European heart journal.

[2]  N. Danchin,et al.  Trends in cardiogenic shock complicating acute myocardial infarction , 2020, European journal of heart failure.

[3]  Akshay S. Desai,et al.  Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. , 2019, The New England journal of medicine.

[4]  E. Braunwald,et al.  Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure , 2019, The New England journal of medicine.

[5]  Marco Valgimigli,et al.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). , 2018, European heart journal.

[6]  G. Sulo,et al.  Heart Failure Complicating Acute Myocardial Infarction; Burden and Timing of Occurrence: A Nation‐wide Analysis Including 86 771 Patients From the Cardiovascular Disease in Norway (CVDNOR) Project , 2016, Journal of the American Heart Association.

[7]  J. McMurray.  Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances , 2015, European journal of heart failure.

[8]  Mark D. Huffman,et al.  AHA Statistical Update Heart Disease and Stroke Statistics — 2012 Update A Report From the American Heart Association WRITING GROUP MEMBERS , 2010 .

[9]  A. Jaffe,et al.  A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2015 .

[10]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[11]  P. Heuschmann,et al.  Supplementary Appendix , 2015 .

[12]  K. Alexander,et al.  Influence of heart failure symptoms and ejection fraction on short- and long-term outcomes for older patients with non-ST-segment elevation myocardial infarction. , 2014, American heart journal.

[13]  Jane A. Linderbaum,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[14]  Harlan M Krumholz,et al.  What Distinguishes Top-Performing Hospitals in Acute Myocardial Infarction Mortality Rates? , 2011, Annals of Internal Medicine.

[15]  J. McMurray,et al.  Heart failure after acute myocardial infarction: a lost battle in the war on heart failure? , 2008, Circulation.

[16]  S. Yusuf,et al.  Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.

[17]  S. Solomon,et al.  Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. , 2008, European heart journal.

[18]  L. Køber,et al.  Different angiotensin-converting enzyme inhibitors have similar clinical efficacy after myocardial infarction. , 2008, British Journal of Clinical Pharmacology.

[19]  I. Piña.  Valsartan in acute myocardial infarction trial. , 2004, Current cardiology reports.

[20]  Karl Swedberg,et al.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.

[21]  M. Pfeffer,et al.  Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. , 2003, Journal of the American College of Cardiology.

[22]  Salim Yusuf,et al.  Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study , 2003, Circulation.

[23]  K. Dickstein,et al.  Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial , 2002, The Lancet.

[24]  H. Dargie,et al.  Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial , 2001, The Lancet.

[25]  Salim Yusuf,et al.  Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients , 2000, The Lancet.

[26]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[27]  K. Catt,et al.  Angiotensin receptors and their antagonists. , 1996, The New England journal of medicine.

[28]  Therapy Study Investigators.  Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure , 1993, The Lancet.

[29]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[30]  B. Pitt,et al.  EPLERENONE POST-ACUTE MYOCARDIAL INFARCTION HEART FAILURE EFFICACY AND SURVIVAL STUDY INVESTIGATORS. EPLERENONE, A SELECTIVE ALDOSTERONE BLOCKER, IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION , 2003 .

[31]  S. Yusuf,et al.  Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53. , 2000 .